News

December 21, 2021

Vator Securities advises Cyxone on 67 MSEK Rights Issue

Cyxone is a Swedish clinical stage medicine platform company focused on developing and advancing novel solutions for patients suffering from severe autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS). “The proceeds from the Rights Issue will enable us to implement the next important steps in the development of Cyxone’s new treatment for rheumatoid arthritis (RA). We have a solid and well-structured plan for delivering value creation to our shareholders and to patients world-wide, and our experienced team are now looking forward to take the Company to the next level,” comments Tara Heitner, CEO, Cyxone.

» Read more

December 17, 2021

Vator Securities advises Idogen on 50 MSEK Rights Issue

Idogen is a Swedish biotechnology company that develops tolerogenic cell therapies with the aim of treating unwanted activation of the immune system. The Company conducts three development areas with a focus on treating patients with unwanted activation of the immune system. For the most advanced candidate, IDO 8, intended for patients with severe hemophilia and with antibodies against their treatment, the company’s intention is to submit an application for approval to start a clinical phase I/IIa study in December 2021.

» Read more

November 30, 2021

Vator Securities advises Precise Biometrics on 23 MSEK Directed Share Issue

Precise Biometrics is a global identification software provider, offering products with a range of application for identification in a convenient and secure way. Precise offers products with various applications that enable individuals to identify themselves by using biometrics. Precise intends to use the net proceeds from the directed issue to finance part of the company’s acquisition of EastCoast Solutions.

» Read more

October 29, 2021

Vator Securities advises SenzaGen on 30 MSEK Directed Share Issue

SenzaGen aims to be a leader in non-animal toxicology testing driving the transition from animal testing to methods better suited to reflect human biology. The company has a growth strategy which involve continued commercialization of the in house developed GARD® test platform, expansion of the test portfolio with a broader range of tests and pursuing acquisition opportunities of profitable and growing companies with complementary offerings

» Read more

September 7, 2021

Vator Securities advises Sprint Bioscience on 67 MSEK Rights Issue

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 67,6 million. Sprint Bioscience develops small-molecule first-in-class drug projects with a focus on oncology. Using fragment-based drug discovery, the company develops drug projects in a time- and resource-efficient way. These are then out-licensed to global drug companies during the preclinical phase.

» Read more

July 26, 2021

Vator Securities advises Umecrine Cognition on 35 MSEK Private Placement

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 35,1 million. Umecrine Cognition is developing golexanolone, a drug candidate with a completely new type of mechanism of action targeting the GABAA receptor in the brain.

» Read more

July 12, 2021

Vator Securities advises Plastics Unbound on 30 MSEK Private Placement

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 30,3 million. Plastics Unbound has successfully completed technical and commercial validation through Tier-1 customer trials and production applications and is now transitioning into larger volume orders.

» Read more

July 9, 2021

Vator Swiss Nordic Bio 2022

VATOR SWISS NORDIC BIO 2022 – The Leading Annual European Healthcare Investor Summit in Zürich. Vator Securities and Business Sweden & partners have the pleasure to invite you to the annual European healthcare investor conference VATOR SWISS NORDIC BIO, connecting fast growing Nordic publicly listed healthcare companies, the most exciting start-ups, and the European investor community

» Read more

June 17, 2021

Vator Securities advises Xintela on 28 MSEK Directed Share Issues

Vator Securities acts as Sole Bookrunner in connection with the transactions raising SEK approximately SEK 28 million. Xintela is developing novel stem cell therapies and antibody based targeted cancer therapies using on the integrin marker technology platform XINMARK®. The patented stem cell product XSTEM®, produced in Xintela’s own GMP-facility, is entering a clinical phase I/IIa study in 2021. 

» Read more

June 11, 2021

Vator Securities advises JonDeTech on 32 MSEK Directed Share Issues

Vator Securities acts as Sole Bookrunner in connection with the transaction raising SEK approximately SEK 32,4 million. JonDeTech is a Swedish company that develops and markets patented IR sensor technology based on nanotechnology. The company's IR sensors are down to a tenth as thick as conventional sensors, produced in plastic and can be manufactured in high volumes at a low cost, which opens for a variety of applications in, among other things, consumer electronics and mobile phones. 

» Read more

June 10, 2021

Vator Securities advises ZignSec on 141 MSEK Directed Share Issues

Vator Securities acts as Global Coordinator and Sole Bookrunner in connection with the transactions raising SEK approximately SEK 141 million. The share issues are directed to a number of Swedish and international investors, including Lloyd Fonds, Altitude Capital, Consensus Asset Management and Knutsson Holdings.

» Read more

June 2, 2021

Boris Kotur joins Vator Securities as an Associate managing ECM transactions

Today, Boris Kotur joins Vator Securities as an Associate managing ECM transactions within our Corporate Finance team. Having spent the past four years with Vinge, one of the leading Swedish law firms, we are very excited to have Boris joining us. Hereby adding further talent to our platform serving our clients.

» Read more

June 1, 2021

Vator Tech Days – Focus: Technologies of Tomorrow

Vator Securities welcomes you to VatorTech Days - Technologies of Tomorrow, a digital event where you will have the opportunity to meet some of the most exciting companies working with the technology of the future in renewable energy and sustainable innovations. The event takes place on June 9th at 09:00 to 15:00. Among the participating companies are PowerCell Sweden, Soltech Energy Sweden, Re:Newcell, Nexam Chemical, Ljusgårda, Minesto, JonDeTech Sensors, Swedish Stirling AB, OXE Marine och Sivers Semiconductors.

» Read more

May 31, 2021

Vator Securities advises SciBase on 71 MSEK Directed Share Issues

Vator Securities acts as Sole Bookrunner in connection with the transactions raising SEK approximately SEK 71 million. The share issues are directed to a number of Swedish and international investors, including Van Herk Investments B.V. and ÖstVäst Capital Management, amongst others.

» Read more

May 28, 2021

Four new partners at Vator Securities

Vator Securities was established ten years ago and continues to expand. Hereby the promotion of four employees to new partners is announced: Erik Sjöström, Erik Röjvall, Felicia Rittemar, and Anders Arviken.  Through our new partners, Vator Securities further broadens and strengthens our knowledgebase. Acceding partners contribute with many years of professional experience and broad knowledge about, among other things, share analysis, project management, investment activities, and share management.

» Read more

May 6, 2021

Vator Tech Days – Focus: Gaming

Vator Securities welcomes you to Vator Tech Days – Focus: Gaming, a digital event where you get the opportunity to meet the most exciting fast-growing companies within Gaming and Esport. The event takes place on May 26th at 09:00 to 16:45. Among the participating companies are  Modern Times Group, Enad Global 7, Media and Games Invest, Thunderful Group, 11 Bit Studios (PL), Epulze, Flexion, Adverty, Qiiwi, Safe Lane Gaming, and MAG Interactive.

» Read more